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p://dx.doi.org/10.1016/j.nmni.2015.05.004Carbapenems are frequently used as last drug choice for the
treatment of multidrug-resistant Pseudomonas aeruginosa in-
fections [1], but the emergence of carbapenem resistance is
increasingly reported. Carbapenem resistance in P. aeruginosa
may be due to low permeability, multidrug efﬂux pumps or the
production of class B β-lactamases (metallo-β-lactamases, MBLs)
[2]. However, the main mechanism of carbapenem resistance in
P. aeruginosa remains the loss or the alteration of the outer
membrane porin (oprD) through mutations, deletions or in-
sertions in the oprD gene [3]. Clinical isolate of P. aeruginosa
exhibiting high-level resistance to carbapenems was isolated
from a sputum sample of a 69-year-old man with idiopathic
pulmonary ﬁbrosis treated by the association of either cipro-
ﬂoxacin or ceftazidime or tazocillin with tobramycin or col-
imycin and later by imipenem. Strain (PA 461) was cultured on
trypticase soy agar plate at 37°C for 24 hours, and identiﬁcation
was conﬁrmed by matrix-assisted desorption ionization–time of
ﬂight mass spectrometry (MALDI-TOF MS) (Microﬂex; Bruker
Daltonics, Bremen, Germany) with FlexControl software, as
previously described [4]. Antibiotic susceptibility testing per-
formed on Mueller-Hinton agar by standard disk diffusion
method as recommended by the European Committee on
Antimicrobial Susceptibility Testing (EUCAST; http://www.
eucast.org/), showed that the isolate was resistant to almost all
antibiotics, including β-lactams, as well as ﬂuoroquinolones and
rifampicin, but remained susceptible to aminoglycosides and
colistin. Phenotypic detection of carbapenemase by modiﬁed
Hodge test and imipenem–ethylene diamine tetra-acetic acid
test, performed as previously described [5], were negative. The
presence of MBLs genes, investigated by PCR as previously
described [6], conﬁrmed that this isolate did not produce a
carbapenemase. Ampliﬁcation of the oprD gene using previously
described primers [3,6] resulted in PCR product of 2.6 kb
instead of 1332 bp. Sequence analysis of the 2668 bp product
revealed insertion of a sequence of 1336 bp at position 610 in
oprD. Within the sequence, an open reading frame of 1227 bp
was found and corresponded to ISPa1328 from P. aeruginosa
(GenBank accession AY539833). This insertion sequence (IS)
was bordered by two terminal imperfect repeats and ﬂanked on
both sides by direct repeat sequences of 7 bp (CCAAGAG)
(Fig. 1). Multilocus sequence typing, performed as previously
described (http://pubmlst.org/paeruginosa), showed a novel
sequence type (ST1797) and thus a novel clone of P. aeruginosa.
Random transposition of IS elements is known to be a form
of adaptation of bacteria to environmental changes. To date, the
presence of IS elements disrupting the oprD gene has been
reported in South Africa (ISPa26) [7], Spain (ISPa133) [8], China
(ISPa1328, ISPre2) [9], the United States (ISPa8 [1] and ISPa1328
[10]) and France (ISPa46) [6]. The occurrence of multidrug-European Society of Clinical Microbiology and Infectious Diseases
nses/by-nc-nd/4.0/)
FIG. 1. Schematic representation of oprD gene of PA461 disrupted by ISPa1328 compared to reference strain PAO1.
NMNI Letter to the Editor 27resistant bacteria is associated with the extensive use of broad-
spectrum antimicrobial drugs in treating humans. This could
explain the emergence of imipenem-resistant P. aeruginosa in
this patient, the result of direct and speciﬁc antibiotic selective
pressure created by the use of imipenem.
In conclusion, we report for the ﬁrst time in France the
emergence of ISPa1328 in a patient with idiopathic pulmonary
ﬁbrosis associated with carbapenem resistance.Conﬂict of interestNone declared.AcknowledgementThe authors thank L. Hadjadj for technical assistance.References[1] Fowler RC, Hanson ND. Emergence of carbapenem resistance due to
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